Is resection for noncolorectal, nonneuroendocrine liver metastases justified?

Patkar, Shraddha; Niyogi, Devayani; Parray, Amir; Goel, Mahesh

doi:10.1002/jso.26373

Cited by 2 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, we were not able to identify any factors that significantly impaired overall survival following surgery on NCRNNELM. This finding was in line with the recent publications of Patkar et al and Lok et al with similar sample sizes [ 37 , 38 ]. This suggested that patients with NCRNNELM could benefit from radical treatment in the long run.…”

Section: Discussionsupporting

confidence: 93%

Surgery for Liver Metastasis of Non-Colorectal and Non-Neuroendocrine Tumors

Katou

Schmid

Silveira

et al. 2022

JCM

View full text Add to dashboard Cite

Surgery has become well established for patients with colorectal and neuroendocrine liver metastases. However, the value of this procedure in non-colorectal and non-neuroendocrine metastases (NCRNNELMs) remains unclear. We analyzed the outcomes of patients that underwent liver surgery for NCRNNELMs and for colorectal liver metastases (CRLMs) between 2012 and 2017 at our institution. Prognostic factors of overall and recurrence-free survival were analyzed, and a comparison of survival between two groups was performed. Seventy-three patients (30 NCRNNELM and 43 CRLM) were included in this study. Although the mean age, extrahepatic metastases, and rate of reoperation were significantly different between the groups, recurrence-free survival was comparable. The 5-year overall survival rates were 38% for NCRNNELM and 55% for CRLM. In univariate analysis, a patient age of ≥60 years, endodermal origin of the primary tumor, and major complications were negative prognostic factors. Resection for NCRNNELM showed comparable results to resection for CRLM. Age, the embryological origin of the primary tumor, and the number of metastases might be the criteria for patient selection.

show abstract

Section: Discussionsupporting

confidence: 93%

Surgery for Liver Metastasis of Non-Colorectal and Non-Neuroendocrine Tumors

Katou

Schmid

Silveira

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Previous studies have reported favorable outcomes in patients with breast cancer who underwent resection of brain [ 12 , 13 ] and bone metastases [ 14 ]. Hence, surgical resection may be a promising treatment option in cases of breast cancer with liver metastases (BCLM) [ 15 ]. Recent studies have demonstrated that liver resection can improve survival beyond 5 or 10 years after BCLM surgery [ 16 – 19 ].…”

Section: Introductionmentioning

confidence: 99%

Does hepatectomy improve outcomes of breast cancer with liver metastasis? A nationwide analysis of real-world data in Taiwan

Chen

Lee

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Background Liver metastases from breast cancer are associated with poor prognosis, and treatment options are usually restricted to palliative systemic therapy. The impact of liver resection on metastasis remains controversial. The aim of this study is to investigate whether liver resection can offer better survival outcomes in cases of isolated liver metastases from breast cancer. Methods We conducted a nationwide cohort study using a claims dataset from Taiwan’s National Health Insurance Research Database (NHIRD). We identified all patients with breast cancer (diagnostic code ICD-9: 174.x) from the Registry for Catastrophic Illness Patient Database (RCIPD) of the NHIRD who underwent mastectomy between January 1, 2000, and December 31, 2008. Patients with other malignancies (history, initially, or during follow-up), those with a history of metastasis prior to or at initial admission for mastectomy, and those without liver metastases were excluded. Patients with other metastases between mastectomy and liver metastasis and those who died at first admission for liver resection were also excluded. All patients were followed up until December 31, 2013, or withdraw from the database because of death. Results Data were analyzed for 1,116 patients who fulfilled the inclusion criteria (resection group: 89; non-resection group: 1,027). There were no differences in age, Charlson Comorbidity Index, or major coexisting diseases except renal disease between two groups. Kaplan–Meier analysis demonstrated that the liver resection group had significantly better overall survival (OS) than the non-resection group. (1-year: 96.6% vs. 52.3%, 2-year: 86.8% vs. 35.4%, 3-year: 72.3% vs. 25.2%, 5-year: 51.6% vs. 16.9%, respectively, p<0.001). Cox analysis revealed that the liver resection group exhibited a significant improvement in patient survival (hazard ratio [HR] = 0.321, 95% confidence interval [CI]: 0.234–0.440, p<0.001). Conclusion These findings indicate that liver resection may offer better survival benefit in patients with breast cancer who develop new liver metastases post mastectomy.

show abstract

Is resection for noncolorectal, nonneuroendocrine liver metastases justified?

Cited by 2 publications

References 9 publications

Surgery for Liver Metastasis of Non-Colorectal and Non-Neuroendocrine Tumors

Surgery for Liver Metastasis of Non-Colorectal and Non-Neuroendocrine Tumors

Does hepatectomy improve outcomes of breast cancer with liver metastasis? A nationwide analysis of real-world data in Taiwan

Contact Info

Product

Resources

About